PharmaShots | Incisive News in 3 Shots

Subscribe Now

Junshi Biosciences

Junshi Biosciences’ Loqtorzi (Toripalimab) Receives the EC’s Approval for Treating Nasopharyngeal Carcinoma (NPC) and Esophageal Squamous Cell Carcinoma (ESCC)

Junshi Biosciences’ Loqtorzi (Toripalimab) Receives the EC’s Approval for Treating Nasopharyngeal Carcinoma (NPC) and Esophageal S...

September 25, 2024

Junshi Biosciences Reports the CHMP’s Positive Opinion of Loqtorzi (Toripalimab) Across Two Indications

Junshi Biosciences Reports the CHMP’s Positive Opinion of Loqtorzi (Toripalimab) Across Two Indications

July 30, 2024

Junshi Biosciences Reports the P-III Trial Data of Toripalimab Plus Bevacizumab to Treat Advanced Hepatocellular Carcinoma (HCC)

Junshi Biosciences Reports the P-III Trial Data of Toripalimab Plus Bevacizumab to Treat Advanced Hepatocellular Carcinoma (HCC)

June 12, 2024

Junshi Biosciences Reports the Result of VV116 in P-III to Treat COVID-19

Junshi Biosciences Reports the Result of VV116 in P-III to Treat COVID-19

November 23, 2023

Junshi Biosciences Reports the NMPA Acceptance of sNDA of Toripalimab as 1L Treatment of Extensive-Stage Small Cell Lung Cancer

Junshi Biosciences Reports the NMPA Acceptance of sNDA of Toripalimab as 1L Treatment of Extensive-Stage Small Cell Lung Cancer

July 20, 2023

Junshi Biosciences Reports the NMPA Acceptance of sNDA for Toripalimab + Axitinib as 1L Treatment of Unresectable or Metastatic Renal Cell Carcinoma

Junshi Biosciences Reports the NMPA Acceptance of sNDA for Toripalimab + Axitinib as 1L Treatment of Unresectable or Metastatic Re...

July 12, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us